Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZW) Capital Expenditures (2021 - 2025)

Core Scientific (CORZW) has disclosed Capital Expenditures for 5 consecutive years, with $279.2 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 871.03% to $279.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $729.0 million through Dec 2025, up 667.68% year-over-year, with the annual reading at $729.0 million for FY2025, 667.68% up from the prior year.
  • Capital Expenditures hit $279.2 million in Q4 2025 for Core Scientific, down from $449.7 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $449.7 million in Q3 2025 to a low of -$116.1 million in Q4 2021.
  • Historically, Capital Expenditures has averaged $61.4 million across 5 years, with a median of $15.3 million in 2023.
  • Biggest five-year swings in Capital Expenditures: tumbled 179.49% in 2022 and later skyrocketed 14773.62% in 2024.
  • Year by year, Capital Expenditures stood at -$116.1 million in 2021, then skyrocketed by 377.1% to $321.6 million in 2022, then crashed by 95.24% to $15.3 million in 2023, then surged by 87.7% to $28.8 million in 2024, then soared by 871.03% to $279.2 million in 2025.
  • Business Quant data shows Capital Expenditures for CORZW at $279.2 million in Q4 2025, $449.7 million in Q3 2025, and $36000.0 in Q1 2025.